Clinical trials: Obese Subjects
Obesity
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
- Trial name
- NCT00479492
- Testing
- CP-866,087
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Pfizer
Healthy Volunteers
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in…
- Trial name
- NCT02855177
- Testing
- PF-06427878
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.
- Trial name
- NCT01444677
- Testing
- MB12066
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Obesity, Overweight
A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
- Trial name
- NCT01540864
- Testing
- HPP404
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- High Point Pharmaceuticals, LLC.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Obesity
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m².
- Trial name
- NCT06745284
- Testing
- Survodutide, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Obesity
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and…
- Trial name
- NCT00819234
- Testing
- Pramlintide and Metreleptin
- Where
- 33 sites in United States
- Volunteers
- 274 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Insulin Glulisine in Healthy Lean and Obese Subjects
Primary objective To investigate pharmacodynamic and pharmacokinetic parameters after s.c. administration of two different doses (low dose, 0.2 IU/kg and high dose, 0.4 IU/kg) of insulin glulisine across healthy subjects in 4…
- Trial name
- NCT00311077
- Testing
- Insulin Glulisine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi
Overweight or Obesity
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.
- Trial name
- NCT06621316
- Testing
- HRS-7535 Tablet
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
- Trial name
- SCOUT (NCT00234832)
- Testing
- Sibutramine hydrochloride
- Where
- United States
- Volunteers
- 10,777 people
- Sponsor
- Abbott
Overweight or Obesity
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
- Trial name
- NCT06973681
- Testing
- BGM0504
- Where
- China
- Volunteers
- 120 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus Type 2
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Trial name
- NCT01807377
- Testing
- PF-05175157, Midazolam
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
- Trial name
- NCT00449202
- Testing
- oleoyl-estrone (MP 101)
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 100 people
- Sponsor
- Manhattan Pharmaceuticals
Obesity
Methods Study to Characterize Early Indicators of Weight Loss in People
Methods study to characterize early indicators of weight loss in people.
- Trial name
- NCT00383253
- Testing
- caloric restriction - 10%, caloric restriction - 25%, caloric restriction - 50%
- Where
- 2 sites in Australia
- Volunteers
- 57 people
- Sponsor
- Pfizer
Prediabetic State, Non-alcoholic Fatty Liver Disease
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes…
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT02330549
- Testing
- Cenicriviroc 150 mg
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Tobira Therapeutics, Inc.
Chronic Management of Body Weight
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
- Trial name
- NCT07670884
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 675 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Central Abdominal Bulging
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.
- Trial name
- NCT02568319
- Testing
- LIPO-202
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Neothetics, Inc
Overweight, Obesity
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity, but it has been approved as a…
- Trial name
- NCT04187300
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline